DTIL
Precision Biosciences Inc

3,717
Mkt Cap
$101.21M
Volume
216,748.00
52W High
$8.82
52W Low
$3.75
PE Ratio
-0.50
DTIL Fundamentals
Price
$4.20
Prev Close
$4.25
Open
$4.23
50D MA
$4.68
Beta
0.77
Avg. Volume
229,073.05
EPS (Annual)
$1.04
P/B
3.05
Rev/Employee
$636,074.07
Loading...
Loading...
News
all
press releases
J. Jefferson Smith Sells 10,200 Shares of Precision BioSciences (NASDAQ:DTIL) Stock
Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) insider J. Jefferson Smith sold 10,200 shares of the firm's stock in a transaction that occurred on Wednesday, January 21st. The shares...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Precision BioSciences (NASDAQ:DTIL) Insider J. Jefferson Smith Sells 10,200 Shares
Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) insider J. Jefferson Smith sold 10,200 shares of the business's stock in a transaction that occurred on Wednesday, January 21st. The shares...
MarketBeat·2d ago
News Placeholder
Precision BioSciences (NASDAQ:DTIL) CFO Sells $61,308.39 in Stock
Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) CFO John Alexander Kelly sold 15,213 shares of the stock in a transaction dated Wednesday, January 21st. The stock was sold at an average...
MarketBeat·2d ago
News Placeholder
Michael Amoroso Sells 34,799 Shares of Precision BioSciences (NASDAQ:DTIL) Stock
Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) CEO Michael Amoroso sold 34,799 shares of the company's stock in a transaction on Thursday, January 22nd. The stock was sold at an average...
MarketBeat·2d ago
News Placeholder
Precision BioSciences (NASDAQ:DTIL) Trading Down 3.8% - Time to Sell?
Precision BioSciences (NASDAQ:DTIL) Shares Down 3.8% - Should You Sell...
MarketBeat·3d ago
News Placeholder
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·13d ago
News Placeholder
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Expands By 27.4%
Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest...
MarketBeat·25d ago
News Placeholder
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for diseases with high unmet...
Business Wire·1mo ago
News Placeholder
Insider Buying: Precision BioSciences (NASDAQ:DTIL) Director Acquires $12,690.00 in Stock
Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) Director Stanley Frankel acquired 2,700 shares of the company's stock in a transaction that occurred on Tuesday, December 16th. The shares...
MarketBeat·1mo ago
News Placeholder
Precision BioSciences (NASDAQ:DTIL) Trading 4.9% Higher - Time to Buy?
Precision BioSciences (NASDAQ:DTIL) Stock Price Up 4.9% - Still a Buy...
MarketBeat·2mo ago
<
1
2
...
>

Latest DTIL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.